Holen Sie sich die Stockscreener-App
6.90
1.57%
-0.11
Handel nachbörslich:
6.90
Schlusskurs vom Vortag:
$7.01
Offen:
$7.04
24-Stunden-Volumen:
1.50M
Relative Volume:
0.48
Marktkapitalisierung:
$767.70M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-6.1607
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+1.92%
1M Leistung:
+3.29%
6M Leistung:
+192.37%
1J Leistung:
-37.39%
1-Tages-Spanne:
$6.80
$7.19
1-Wochen-Bereich:
$6.60
$7.42
52-Wochen-Spanne:
$1.03
$12.02
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
6.90 | 803.30M | 42.51M | -116.49M | -120.82M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
| 2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
| 2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
Live Scanner Shows Breakout on Tango Therapeutics Inc.Wall Street Watch & Verified Chart Pattern Signals - thegnnews.com
Statistical indicators supporting Tango Therapeutics Inc.’s strengthWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser
How to track smart money flows in Tango Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Movement Reports - Newser
Visualizing Tango Therapeutics Inc. stock with heatmapsJuly 2025 Earnings & Verified High Yield Trade Plans - Newser
Tango Therapeutics Inc. recovery potential after sell off2025 Buyback Activity & Weekly Chart Analysis and Guides - Newser
Is This a Bottoming Phase for Tango Therapeutics Inc.Earnings Growth Report & Free Safe Entry Trade Signal Reports - newsyoung.net
Advanced analytics toolkit walkthrough for Tango Therapeutics Inc.Sell Signal & Technical Analysis for Trade Confirmation - Newser
How to forecast Tango Therapeutics Inc. trends using time seriesPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Analyzing recovery setups for Tango Therapeutics Inc. investorsMarket Performance Recap & Risk Controlled Stock Alerts - Newser
Full technical analysis of Tango Therapeutics Inc. stockWeekly Trend Recap & Weekly High Potential Alerts - Newser
Analyzing drawdowns of Tango Therapeutics Inc. with statistical tools2025 Volatility Report & Free Expert Verified Stock Movement Alerts - Newser
Tango Therapeutics Inc. stock chart pattern explained2025 Growth vs Value & AI Enhanced Trading Signals - Newser
Applying big data sentiment scoring on Tango Therapeutics Inc.Fed Meeting & Safe Entry Zone Tips - Newser
Tango Therapeutics Inc. stock trend forecastQuarterly Profit Report & Expert Approved Momentum Trade Ideas - Newser
Using Python tools to backtest Tango Therapeutics Inc. strategiesWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Risk vs reward if holding onto Tango Therapeutics Inc.Trade Volume Summary & Short-Term High Return Ideas - Newser
Can technical indicators confirm Tango Therapeutics Inc.’s reversal - Newser
Piper Sandler initiates Tango Therapeutics stock with Overweight rating - Investing.com
What’s next for Tango Therapeutics Inc. stock price2025 Earnings Surprises & Risk Adjusted Buy/Sell Alerts - Newser
Can Tango Therapeutics Inc. stock recover from recent declineWeekly Profit Recap & Capital Efficiency Focused Ideas - Newser
Tango Therapeutics Inc. Shows Risk Reward Favoring UpsideInflation Watch & Risk Managed Trade Strategies - beatles.ru
How moving averages guide Tango Therapeutics Inc. tradingJuly 2025 Review & Entry Point Confirmation Alerts - Newser
What Fibonacci levels say about Tango Therapeutics Inc. reboundJuly 2025 Pullbacks & Weekly High Return Opportunities - Newser
What machine learning models say about Tango Therapeutics Inc.2025 Market WrapUp & Fast Momentum Stock Entry Tips - Newser
Why Tango Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Opening Moves & Expert Curated Trade Setups - Newser
Can swing trading help recover from Tango Therapeutics Inc. lossesJuly 2025 Technicals & Long-Term Safe Investment Ideas - Newser
Analyzing Tango Therapeutics Inc. with risk reward ratio charts2025 Technical Overview & Fast Entry High Yield Stock Tips - Newser
Applying Elliott Wave Theory to Tango Therapeutics Inc.July 2025 Opening Moves & Fast Entry and Exit Trade Plans - Newser
Price action breakdown for Tango Therapeutics Inc.Market Risk Summary & Technical Buy Zone Confirmations - Newser
Technical Charts Suggest Momentum Shift in Tango Therapeutics Inc. - sundaytimes.kr
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tango Therapeutics Inc-Aktie (TNGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barry Douglas | General Counsel |
Feb 04 '25 |
Sale |
2.99 |
2,774 |
8,289 |
68,570 |
| Barry Douglas | General Counsel |
Feb 05 '25 |
Sale |
3.16 |
2,556 |
8,081 |
66,014 |
| Beckman Daniella | Chief Financial Officer |
Feb 04 '25 |
Sale |
2.99 |
4,284 |
12,801 |
154,232 |
| Beckman Daniella | Chief Financial Officer |
Feb 05 '25 |
Sale |
3.16 |
3,948 |
12,481 |
150,284 |
| Crystal Adam | See Remarks |
Feb 04 '25 |
Sale |
2.99 |
7,432 |
22,207 |
165,061 |
| Crystal Adam | See Remarks |
Feb 05 '25 |
Sale |
3.16 |
6,851 |
21,659 |
158,210 |
| Weber Barbara | Chief Executive Officer |
Feb 04 '25 |
Sale |
2.99 |
9,778 |
29,217 |
1,631,264 |
| Weber Barbara | Chief Executive Officer |
Feb 05 '25 |
Sale |
3.16 |
9,013 |
28,494 |
1,622,251 |
| Rothenberg Mace | Director |
Nov 18 '24 |
Buy |
3.78 |
10,000 |
37,800 |
31,250 |
| Rothenberg Mace | Director |
Nov 14 '24 |
Buy |
3.62 |
10,000 |
36,200 |
21,250 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):